Virax Biolabs Approves 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing
VRAX sits 34% above its 52-week low of $0.1 on light trading volume (0.1× avg).
Summary
Virax Biolabs announced its board approved a 1-for-25 reverse stock split, effective June 26, 2026, to meet Nasdaq's minimum bid price requirement and maintain its listing.
Key Events · Corporate Governance and Compliance · VRAX
-
Reverse Stock Split Approved
The board of directors approved a 1-for-25 share consolidation (reverse stock split), effective June 26, 2026.
-
Nasdaq Compliance Objective
The primary objective of the reverse split is to regain compliance with Nasdaq Marketplace Rule 5550(a)(2), which requires a minimum bid price of $1 per share, thereby maintaining the company's listing.
-
Shareholder Approval Confirmed
This board action follows the approval by shareholders at an Extraordinary General Meeting held on June 12, 2026, which authorized a reverse split within a range of 1-for-10 to 1-for-30.
Analysis · VRAX · Life Sciences
The board's approval of a 1-for-25 reverse stock split, effective June 26, 2026, is a critical step for Virax Biolabs to regain compliance with Nasdaq's minimum bid price requirement. While necessary to avoid delisting, reverse splits are generally viewed negatively by the market as they often indicate underlying challenges and can lead to further share price volatility. This action finalizes the specific terms of the split previously approved by shareholders.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VRAX was trading at $0.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.10 to $1.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.